骨质疏松治疗中地舒单抗与唑来膦酸的临床应用进展与挑战  

Progress and challenges in the clinical application of denosumab and zoledronic acid in the treatment of osteoporosis

作　　者：王巧梅 崔永建[1] Wang Qiaomei;Cui Yongjian(Sixth Affiliated Hospital of Xinjiang Medical University,Urumqi,Xinjiang 830000,China)

机构地区：[1]新疆医科大学第六附属医院,新疆乌鲁木齐830000

出　　处：《首都食品与医药》2025年第8期23-25,共3页Capital Food Medicine

摘　　要：近些年来,随着人口老龄化的加剧,骨质疏松发病率逐年上升。老年人是骨质疏松的主要发病群体,对老年人的身体健康产生较大影响,目前已成为全球性的重要公共卫生问题。就骨质疏松的治疗现状来看,药物、生活方式及营养干预等是常见的传统治疗手段。其中,药物的见效速度快且对骨密度有改善作用。不同药物对骨质疏松的治疗效果也存在差异。地舒单抗、唑来膦酸作为新型骨质疏松治疗药物受到临床高度重视。地舒单抗属于人源性的单克隆抗体,能够增加骨密度。唑来膦酸属于双膦酸盐类药物,对于骨吸收有抑制作用。不过受多种因素的影响,临床对两种药物仍存在认识不足的现象。基于此,本研究对前人学者的相关研究成果进行归纳,总结成综述如下。In recent years,with the aggravation of population aging,the incidence rate of osteoporosis has increased year by year.The elderly are the main population affected by osteoporosis,which has a significant impact on their physical health and has become a global public health issue.In terms of the current treatment status of osteoporosis,medication,lifestyle,and nutritional interventions are common traditional treatment methods.Among them,the drug has a fast onset of action and has an improving effect on bone density.Different drugs have varying therapeutic effects on osteoporosis.Denosumab and zoledronic acid,as novel osteoporosis treatment drugs,have received high clinical attention.Denosumab is a humanized monoclonal antibody that can increase bone density.Zoledronic acid belongs to the class of bisphosphonates and has an inhibitory effect on bone resorption.However,due to various factors,there is still a lack of understanding of the two drugs in clinical practice.Based on this,this study summarizes the relevant research results of previous scholars as follows.

关 键 词：骨质疏松 地舒单抗 唑来膦酸 

分 类 号：R681[医药卫生—骨科学]